Chemomab Therapeutics Ltd. Banner Image

Chemomab Therapeutics Ltd.

  • Ticker CMMB
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Chemomab Therapeutics Ltd. Logo Image
  • 11-50 Employees
  • Based in Tel Aviv-Yafo, Israel
Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the chemokine CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies to dateMore, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported encouraging results from a Phase 2 liver fibrosis study in NASH patients and an investigator study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis patients is ongoing.
4.8 / 5.0 (64)

Chemomab Therapeutics Ltd. reports have an aggregate usefulness score of 4.8 based on 64 reviews.

Chemomab Therapeutics Ltd.

Most Recent Annual Report

Chemomab Therapeutics Ltd.
MOST RECENT 2023 Annual Report, 2022 Form 10K

Older/Archived Annual Reports

Chemomab Therapeutics Ltd. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!